Calcipotriene
As of the edition of 20 October 2026, Calcipotriene is a small molecule: marketed, first approved in 1992 (FR); acts on VDR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2023
- Kind
- Small molecule
- Brand name
- Dovonex
- First approved
- 25 May 1992 (FR)
- Approvals on record
- 17 in 7 regions
- Holder of the most recent approval
- Almirall; 10 holders in all
- Registered trials
- 82, 8 stopped early
- Disease areas
- Skin and connective tissue; Cancer; Immune system; Chemically induced; Blood and lymph; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Calcipotriene.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| VDR | Vitamin D3 receptor | P11473 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 12 | 8 | 3 | 0 |
| Phase 1 | 20 | 14 | 1 | 4 |
| Phase 2 | 13 | 9 | 1 | 2 |
| Phase 3 | 18 | 15 | 1 | 1 |
| Phase 4 | 19 | 11 | 6 | 1 |
| All trials | 82 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| LEO Pharma | Applicant, Acquired holder and Lead sponsor of trials | 1992 to now |
| Bristol Myers Squibb | Applicant | 1993 to now |
| Leo Pharmaceutical | Acquired holder | 2006 to now |
| Stiefel | Later holder | 2010 to now |
| Pfizer | Acquired holder and Lead sponsor of trials | 2012 to now |
| Almirall | Applicant | 2023 to now |